Synovial fibroblast niche shapes the efficacy - safety dynamics of JAK inhibition in rheumatoid arthritis
This study identifies synovial fibroblasts as primary targets of JAK inhibition in rheumatoid arthritis, revealing how specific fibroblast subsets and cytokine-driven signaling mechanisms (such as TNF/IL-6 synergy and STAT uncoupling) determine the therapeutic efficacy, functional ceiling, and withdrawal risks of JAK inhibitors.